Thompson Siegel & Walmsley LLC Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Thompson Siegel & Walmsley LLC reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.6% in the 2nd quarter, Holdings Channel.com reports. The firm owned 8,978 shares of the pharmaceutical company’s stock after selling 634 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Vertex Pharmaceuticals were worth $3,159,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of VRTX. Sandy Spring Bank lifted its position in shares of Vertex Pharmaceuticals by 1,014.3% during the 1st quarter. Sandy Spring Bank now owns 78 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 71 shares during the last quarter. Independence Bank of Kentucky acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $25,000. Marquette Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the 2nd quarter worth $27,000. Compass Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth $29,000. Finally, Quent Capital LLC raised its stake in Vertex Pharmaceuticals by 91.1% during the 2nd quarter. Quent Capital LLC now owns 86 shares of the pharmaceutical company’s stock worth $30,000 after acquiring an additional 41 shares in the last quarter. 90.77% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Ourania Tatsis sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $355.00, for a total value of $887,500.00. Following the completion of the transaction, the executive vice president now owns 48,637 shares of the company’s stock, valued at $17,266,135. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Ourania Tatsis sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $355.00, for a total transaction of $887,500.00. Following the completion of the transaction, the executive vice president now owns 48,637 shares of the company’s stock, valued at $17,266,135. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Jeffrey M. Leiden sold 12,962 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $374.00, for a total transaction of $4,847,788.00. Following the transaction, the chairman now directly owns 22,425 shares of the company’s stock, valued at approximately $8,386,950. The disclosure for this sale can be found here. Insiders sold a total of 50,411 shares of company stock valued at $18,511,525 over the last 90 days. Insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on VRTX. HC Wainwright lifted their price target on shares of Vertex Pharmaceuticals from $380.00 to $390.00 and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Sanford C. Bernstein lifted their price target on shares of Vertex Pharmaceuticals from $380.00 to $390.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 2nd. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $384.00 to $399.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 2nd. BMO Capital Markets lifted their price target on shares of Vertex Pharmaceuticals from $389.00 to $415.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Finally, Wells Fargo & Company lifted their price objective on shares of Vertex Pharmaceuticals from $410.00 to $425.00 and gave the company an “overweight” rating in a research note on Wednesday, August 2nd. Seven research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $376.13.

Vertex Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ VRTX opened at $350.50 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $282.21 and a 12-month high of $387.42. The company has a market capitalization of $90.32 billion, a PE ratio of 26.29, a price-to-earnings-growth ratio of 2.28 and a beta of 0.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.08 and a quick ratio of 3.89. The firm’s 50-day moving average is $360.28 and its two-hundred day moving average is $350.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 6th. The pharmaceutical company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.53 by $0.55. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 35.94% and a return on equity of 22.79%. The company’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.62 earnings per share. Equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 13.61 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.